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Definition of personalized medicine is not an easy issue [1-3, 101]. It is moving from 
personalized medical practice to the modern concept of personalizing the science of 
medicine to improve individual healthcare. In many aspects personalized medicine 
refers to translation into clinical medicine and health care person’s unique biological 
individuality and his/her interaction with the environment. By the term personalized 
medicine we envision a complete integration of clinical (phenotype), genetic, genomic, 
transcriptomic, proteomic, metabolomic profiles with environmental (including 
nutritional) information that is provided for a particular person. The major expected 
consequence is to optimize preventive health care strategies and response to drug 
therapies while people are either healthy or in an early stage of the disease. 
Personalized medicine tries to move the population-based evidence of medical 
interventions towards individual evidence of how to treat the specific person based on 
the biological profile, clinical history and environment. The aim is to offer a tailored 
healthcare to every person. The personalized medicine based on the integration of 
individual information, from the genome variation, physiology and cellular phenotype to 
the interaction with the personal environment, may represent a proactive, preventive 
and prospective model of health care [4-6] by opposite to the more traditional, disease-
based, reactive approach to the health status of individuals.    
The fundamentals of genomic and personalized medicine and application of 
new technologies that may define personal biological profiles apply to every type of 
pathological process, disease or condition, whatever the main organ or tissue is 
involved in the disorder affecting the person. Personalized medicine today is 
addressing a number of elements that are relevant to any kind of disease. Such 
elements have to be considered when we are thinking in a prospective model of health 
care and generation of predictive markers. They include basic research and 
technologies development (most of them based on ‘omics’ approaches), translational 
research and characterization of biomarkers, further clinical application of new 
  
translational tools, and social and ethical impact. However, the impact of personalized 
medicine has not been identical in all clinical areas. Traditionally, personalized 
medicine has been in practice in oncology and across other disease specialisms 
involving common diseases such as cardiovascular disorders, diabetes and metabolic 
syndrome, and neurodegenerative diseases. In addition, in the recent years rare 
diseases (RD) have become an important field of interest for both translational 
research and the application of personalized medicine approach to individual patients. 
How personalized medicine may be incorporated in the health care of RD? Are the 
premises and fundamentals identical among RD to the common diseases (CD)? Which 
are the main differences among RD and CD for the individual application of 
personalized medicine? To address these questions we need to answer some 
elements of medical thinking by responses that characterize RD. 
 
Elements for a conceptual framework of rare diseases 
By ‘rare diseases’ we refer to non-frequent disorders or conditions with a low 
prevalence that in the European Union has been estimated of less than 5 patients per 
10,000 inhabitants. According to that definition, RD affect 6-8% of the Europe’s 
population, that is, around 30 million people in the EU-27 are affected. Despite their low 
frequency these diseases show some common characteristics, which allow integrating 
individuals affected by a RD as a social group that share common health and social 
problems [7, 102, 103]. There are important factors to take in account when thinking in 
a RD: (i) they used to be severe, chronic and progressive disorders with a high degree 
of incapacity; (ii) in spite of they are not common disorders RD are complex 
pathological conditions, and (iii) in most cases, RD are genetic disorders that express 
the first symptoms at the pediatric age.  
  
The individual patient and also patients as a whole increasingly own their life 
and their ability to make decisions, with appropriate information and autonomy; in some 
way it can be stated that they are personalized decisions. The empowerment that 
patients have on their own illness, based on their experience and knowledge of life, 
makes them fundamental for the management of the disease and the lifestyle 
according to their needs. No matter how we define the RD, patients have much to say 
about them. Some important issues that affect patients and for which they and the lay 
organizations are demanding attention may be summarized as follows [103]: lack of 
scientific knowledge about their illness, difficulty of access to correct diagnosis, delayed 
diagnosis, lack of care and multidisciplinary care, lack of quality information and 
support at the time of diagnosis, adverse social consequences, difficulty and lack of 
equity in access to treatment, rehabilitation and care, loss of confidence in medical and 
social services and a lack of interest from health professionals. 
As mentioned above RD are a broad and heterogeneous group of severe and 
disabling disorders, involving a small number of individuals in specific populations. The 
disease course used to be chronic with high morbidity and mortality, and therapies are 
scarce.  However, there are common diseases showing a chronic and disabling natural 
history, with high morbidity and mortality rate, and limited therapeutic arsenal. Thus, 
what does make the difference among rare diseases and common chronic diseases? 
In the following paragraphs I propose several elements that could help to create a 
single framework of the aspects that characterise rare diseases [8, 104]. These 
elements are important when applying personalized medicine concepts and 
technologies to a person affected by a RD:  
Public health component. Each rare disease has a low prevalence, however, the 
involvement of roughly 30,000,000 people with shared health problems in a population 
as the European Union, requires a scientific approach based on public health criteria 
and premises. This is what has been called the paradox of rarity. 
  
Natural history: diversity and heterogeneity. In a set of clinical conditions as wide 
as RD diversity is an intrinsic feature. The nature of diseases ranges from diseases 
that affect a single organ system until illnesses that are multisystemic. The 
heterogeneity of these diseases is manifested in different profiles of natural history, 
including the age at onset, which determines the clinical intervention and preventive 
health services. 
Multidisciplinary and comprehensive healthcare. A RD is often chronic and 
disabling. In many cases patients with these diseases need care that goes beyond the 
specific clinical care offered by a unique specialized service. This care should be 
considered in the context of overall management, with comprehensive medical and 
psychological care. 
Social and health integrative care. Many RD involve a high degree of dependency 
and social, health and economic burden. This is not something particular to the RD, but 
there are other aspects that are specific to them and give them a certain degree of 
particularity. As previously mentioned, one of these specificities is the age at onset of 
the disease. Most of RD used to express first symptoms early in the biography of 
patients in the pediatric period of life, sometimes between birth and young adult life, 
being early onset the most frequent situation. Thus, in many cases patients require 
health and social care for a very long period of their lives. 
Genetic inheritance. Eighty percent of the RD is estimated to be genetic, mostly 
monogenic, and follow the laws of Mendelian inheritance (also mitochondrial 
inheritance). Knowledge about the genetic causes –mutations- and the underlying 
pathomechanisms are very important to address further research and translation into 
clinical medicine of these diseases. 
Risk of recurrence. Risk of recurrence of a genetic disease on the families makes 
genetic counseling a support and therapeutic tool for these patients and their families, 
which is fundamental for planning reproductive decisions, prenatal diagnosis or 
preimplantational genetic diagnosis. 
  
Geographic dispersion. Except in cases of adverse toxicological, infectious agents or 
other environmental causative factors that may affect a specific population, disease 
used to be present in any population. This is especially true for chronic disorders either 
common or rare. However, the association of both random distribution and low 
prevalence observed for RD is a phenomenon intrinsic to these disorders. This 
circumstance induces the isolation of the patient and the family with no contact with 
other affected people. At the beginning after diagnosis patients or parents may feel that 
they are alone as they never have listen to that disease. Even when they know about 
other patients is very frequent that no more individuals are living close to them. 
Treatment opportunities and development of therapies. Therapeutic options in RD 
are generally scarce and ineffective. However, the development of new therapies and 
drugs for these diseases aimed at specific molecular targets of RD may be useful for 
not only themselves but also for common diseases that may share such biological 
targets or pathophysiogical pathways. 
  
 
Models of medicine and healthcare 
The 20th century introduced modern scientific and experimental knowledge into 
medicine and clinical practice. Even more important, European and other countries 
have developed national health systems to provide care to the population. Childs 
distinguishes two point of view of disease [9]. The Osler’s view of patient as a broken 
machine: historically, in most cases the clinical approach to the patient is based on this 
essentialist view of disease, that is, the patient is represented in the “classical case” 
and the physician is treating the disease but not the individual patient. By contrast, the 
view of Garrod is based on the individuality of the patient: there are no disease, only 
sick people. The individuality (chemical) is that of the patient who represents his or her 
  
own self. However, for both points of view of disease current model in health care is 
still reactive: intervention begins once disease is established either as acute onset or 
acute episodes in chronic diseases. In opposition to the reactive model, even when 
considering the individuality of the patient, Snyderman and colleagues [4-6] propose a 
model of health care based on “the concept of strategic health planning, a non-
reductionist, proactive, prospective approach to care”. In that system, the relevance for 
the individual’s health underlays on the patient’s baseline risk for various diseases 
(familial history may be relevant), his or her health status, and the likelihood of 
developing specific clinical problems regarding the estimated risks. Disease is the 
consequence of multiple factors including genetic susceptibilities and environmental 
exposure (baseline risk). Over time the disease appears and progress from the 
baseline to irreversibility. Specific actions on the individual may help to predict and to 
prevent risks on developing the disease. An outcome of the prospective model is 
disease prediction. In this model demographic, gender, clinical, and family-history 
predictors will probably retain their value. But these are not enough. We need to 
recognize new biomarkers and to define their role on the prognosis of disease and 
response to therapies, and even more relevant to their role on the prediction and 
anticipation of disease. One of the major drivers to discovery predictive factors and 
development of personalized medicine is genomic research and genomic application to 
clinical medicine and health care. Stable gene variation and genome predictors will 
increase baseline clinical risk assessment and the need for primary prevention of a 
particular individual, whereas dynamic factors that show variation over time such as 
mRNA, proteins and metabolites will enhance refined risk assessment giving the 
opportunity to act on the disease progression and guide therapeutic options. Has this 
prospective model identical application to RD than CD? Are there any differences on 
baseline risks and prediction for RD, especially single-gene disorders? 
 
  
A working comparison among rare diseases and common diseases 
To address this point we are comparing the above-mentioned elements of medical 
thinking for both RD and CD. First of all, we have to be aware that boundaries among 
RD and CD are not perfectly established; thus, the adhesion to the criteria is always 
relative and not absolute. The elements appear in Table 1, which contrasts 
characteristics of both types of diseases, separated not only by the criterion of 
frequency but also by the consequences of such a relative prevalence in the 
populations: 
- Most of RD, if any, does not represent by itself a major health problem. However, 
RD as a whole require an approach using the tools of public health as most of 
specific common diseases.  
- Again, most of the RD used to have an early age at onset in infancy, childhood, 
adolescence or early adulthood; by contrast, most of CD used to onset in the 
adulthood or elderly time. Thus, the whole biography of the patient may be affected 
by the disease.  
- It is possible to state that in many cases of RD the individual life has not been free 
of disease. This aspect also involves the need for an integrated social and health 
care programme for a long period of the patient’s life.  
- Almost every disease is related to the genetic background of the individual and the 
interaction between the genomic profile and environmental forces. However, rare 
genetic diseases are single-gene disorders. For the affected individual this 
circumstance represents the baseline to develop the disease. In such a case to be 
carrier of one or two pathogenic mutations almost fully correlated to the appearance 
of the disease. On the contrary, the genetic susceptibility to develop a common 
disease is based on the presence of a number of frequent and/or rare genomic 
variants [10].  
  
- In the previous context, the risk of recurrence of the disease within the family is 
much higher for RD than for CD.  
- Patients for a specific disease are dispersed and there are not any a priori reason to 
expect for it in any population (toxic, infectious diseases or the effect of neck bottle 
of a monogenic disorder may be excluded). But patients affected by a RD are more 
isolated as, at least at diagnosis, they do not know about other person affected by 
the same disease.  
- The interest for drug or therapy development by pharmaceutical companies is 
opposite when comparing RD and CD. The orphan drugs policy in the European 
Union and USA has changed the future of the investment on therapy research on 
RD; in addition, therapeutics research on RD may be the opportunity to new 
solutions not just for the specific RD but also for common diseases that may have 
some pathophysiological connexions with the rare disease. 
 
How we understand personalized medicine in rare diseases 
Based on the elements described above we have showed several aspects that may 
differentiate RD and CD. In fact, differences on the age at onset are very important. 
However, most of the biological and clinical elements related to personalized medicine 
and the prospective model of disease [4-6] are shared by RD and CD. Identification of 
genomic and other omics profiles in every individual either affected or healthy will be 
relevant to design his/her care. Thus, are there any the specific aspect of personalized 
medicine in rare diseases? Part of the answer is already mentioned previously, but 
another one is related to the development of biomarkers (Table 2): whereas common 
diseases may have biological diagnosis (diagnostic biomarkers), few biomarkers are 
available diagnosis of rare diseases. Static genomic biomarkers are relevant for CD as 
they are defining the susceptibility for a trait or disease; the combination of such 
  
genomic variants may increase or decrease the baseline of the disease in the 
individuals of a population. By contrast, the baseline is very low in RD patients with a 
highly penetrant mutation. Dynamic biomarkers to define the prognosis and therapeutic 
response for both CD and RD are also needed. In both cases biomarkers should be 
related to the biological pathways involved in the disease process. Again, a major 
difference among RD and CD is the pivotal role the pathogenic primary mutation in the 
origin and further evolution of the disease.   
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Table 1  Comparison of medical thinking elements  
ELEMENTS  RARE DISEASES  COMMON DISEASES 
The public health 
component 
As a whole, RD are a problem of public 
health 
Every common disease is considered a 
problem of public health  
Natural history – 
age at onset 
Early onset for most of RD have: 
infancy, childhood, adolescence, early 
adulthood 
Late onset in adulthood or elderly age
Health care   Integrative and multidisciplinary model 
but common services shared by 
distinct RD  
Integrative and multidisciplinary model  
but different approach for each CD 
Integrated social 
and health care 
High disease burden because early 
onset (the whole biography of the 
patient may be affected) 
High disease burden because the large 
number of patients 
Genetic 
inheritance 
In most cases, single‐gene inheritance, 
either Mendelian or mitochondrial 
Consequence of genetic and 
environmental interaction 
(complex/multifactorial inheritance) – 
Genetic susceptibility to disease 
Family risk  High risk of recurrence within the 
family 
Low risk of recurrence within the 
family 
Geographical 
distribution 
Patients are dispersed and they may 
feel unique in their own place (except 
in isolated populations) 
Frequent in most populations 
Treatment and 
therapies 
Historically low interest for 
pharmaceutical companies –  
Opportunities for orphan medicines 
High interest for pharmaceuticals 
 
  
Table 2  Differences of biomarkers in rare and common diseases 
MONOGENIC RARE DISEASES  COMMON DISEASES 
The major static (genomic) biomarker is the 
primary pathogenic mutation 
Genomic biomarkers are related to disease 
susceptibility 
Other genetic/genomic variants may be gene 
modifiers of the phenotype expression  
Genetic/genomic variants may represent the 
basis for oligogenic or polygenic inheritance 
of complex traits 
Prediction in mainly based on primary 
mutations and affects family members. 
Dynamic (physiological) biomarkers are 
important for prognosis and therapy 
response 
Prediction is based on dynamic biomarkers as 
prognosis and therapy response are as well 
 
